Better Therapeutics, Inc.

2023 Q4 Form 10-Q Financial Statement

#000095017023061515 Filed on November 09, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $6.598M
YoY Change -70.42%
Cash & Equivalents $6.600M
Short-Term Investments
Other Short-Term Assets $73.00K
YoY Change 17.74%
Inventory
Prepaid Expenses $674.0K
Receivables
Other Receivables
Total Short-Term Assets $7.345M
YoY Change -68.73%
LONG-TERM ASSETS
Property, Plant & Equipment $102.0K
YoY Change -16.39%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $483.0K
YoY Change -1.02%
Total Long-Term Assets $3.377M
YoY Change -28.62%
TOTAL ASSETS
Total Short-Term Assets $7.345M
Total Long-Term Assets $3.377M
Total Assets $10.72M
YoY Change -62.01%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.308M
YoY Change 83.9%
Accrued Expenses $4.044M
YoY Change -17.94%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $6.586M
YoY Change 110.48%
Total Short-Term Liabilities $12.94M
YoY Change 38.94%
LONG-TERM LIABILITIES
Long-Term Debt $7.721M
YoY Change -33.77%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $7.721M
YoY Change -33.77%
TOTAL LIABILITIES
Total Short-Term Liabilities $12.94M
Total Long-Term Liabilities $7.721M
Total Liabilities $20.66M
YoY Change -1.48%
SHAREHOLDERS EQUITY
Retained Earnings -$134.3M
YoY Change 30.77%
Common Stock $124.4M
YoY Change 13.08%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$9.937M
YoY Change
Total Liabilities & Shareholders Equity $10.72M
YoY Change -62.01%

Cashflow Statement

Concept 2023 Q4 2023 Q3

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8629000
dei Entity Central Index Key
EntityCentralIndexKey
0001832415
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39864
dei Entity Registrant Name
EntityRegistrantName
BETTER THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-3472546
dei Entity Address Address Line1
EntityAddressAddressLine1
548 Market St. #49404
dei Entity Address City Or Town
EntityAddressCityOrTown
San Francisco
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94104
dei City Area Code
CityAreaCode
(415)
dei Local Phone Number
LocalPhoneNumber
887-2311
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
BTTX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
47403398
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6598000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15740000
CY2023Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
674000
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2496000
CY2023Q3 us-gaap Other Assets Current
OtherAssetsCurrent
73000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
210000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
7345000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
18446000
CY2023Q3 us-gaap Capitalized Computer Software Net
CapitalizedComputerSoftwareNet
2792000
CY2022Q4 us-gaap Capitalized Computer Software Net
CapitalizedComputerSoftwareNet
3888000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
102000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
121000
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
483000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
488000
CY2023Q3 us-gaap Assets
Assets
10722000
CY2022Q4 us-gaap Assets
Assets
22943000
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2308000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3035000
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1886000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2301000
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2158000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3626000
CY2023Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
6586000
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
4532000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
12938000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
13494000
CY2023Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
7721000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
10348000
CY2023Q3 us-gaap Liabilities
Liabilities
20659000
CY2022Q4 us-gaap Liabilities
Liabilities
23842000
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
40577987
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
40577987
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
23851022
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
23851022
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
4000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
2000
CY2023Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
124370000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
110602000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-134311000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-111503000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-9937000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-899000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
10722000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
22943000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1833000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5477000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7462000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13391000
CY2023Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1392000
CY2022Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1557000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
5200000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
5284000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2116000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3962000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11265000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
5341000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
10996000
us-gaap Operating Expenses
OperatingExpenses
21291000
us-gaap Operating Expenses
OperatingExpenses
29940000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5341000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-10996000
us-gaap Operating Income Loss
OperatingIncomeLoss
-21291000
us-gaap Operating Income Loss
OperatingIncomeLoss
-29940000
CY2023Q3 us-gaap Interest Expense
InterestExpense
518000
CY2022Q3 us-gaap Interest Expense
InterestExpense
406000
us-gaap Interest Expense
InterestExpense
1512000
us-gaap Interest Expense
InterestExpense
1052000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5859000
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-11402000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-22803000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-30992000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3000
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-5862000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-11405000
us-gaap Net Income Loss
NetIncomeLoss
-22808000
us-gaap Net Income Loss
NetIncomeLoss
-30995000
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.15
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.15
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.48
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.48
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.73
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.73
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.32
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.32
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38495150
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38495150
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
23693154
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
23693154
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
31214093
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
31214093
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
23533290
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
23533290
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-899000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-9357000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
423000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-9833000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-7589000
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
6100000
CY2023Q2 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
41000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
493000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-10788000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-5862000
CY2023Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
6279000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
434000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-9937000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
36720000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-9662000
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
1000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
366000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
27425000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-9928000
CY2022Q2 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
145000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
412000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
18054000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-11405000
CY2022Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
6000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
597000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
7252000
us-gaap Profit Loss
ProfitLoss
-22808000
us-gaap Profit Loss
ProfitLoss
-30995000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2393000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2008000
us-gaap Share Based Compensation
ShareBasedCompensation
1315000
us-gaap Share Based Compensation
ShareBasedCompensation
1375000
us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
9000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1965000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-3560000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-727000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-268000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1884000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1718000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-19746000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-22593000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
31000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
92000
us-gaap Payments To Develop Software
PaymentsToDevelopSoftware
927000
us-gaap Payments To Develop Software
PaymentsToDevelopSoftware
728000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-958000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-820000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
13223000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
844000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
27000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
41000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
125000
bttx Proceeds From Issuance Of Long Term Debt Excluding Convertible Debt
ProceedsFromIssuanceOfLongTermDebtExcludingConvertibleDebt
5000000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
858000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
11562000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5152000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-9142000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-18261000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15740000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
40566000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6598000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
22305000
us-gaap Interest Paid Net
InterestPaidNet
1054000
us-gaap Interest Paid Net
InterestPaidNet
870000
CY2023Q3 bttx Medical Costs
MedicalCosts
100000000000
us-gaap Net Income Loss
NetIncomeLoss
-30995000
CY2023Q3 bttx Weighted Average Number Of Shares Outstanding
WeightedAverageNumberOfSharesOutstanding
38505212
CY2022Q3 bttx Weighted Average Number Of Shares Outstanding
WeightedAverageNumberOfSharesOutstanding
23739731
bttx Weighted Average Number Of Shares Outstanding
WeightedAverageNumberOfSharesOutstanding
31250175
bttx Weighted Average Number Of Shares Outstanding
WeightedAverageNumberOfSharesOutstanding
23667335
CY2023Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
10062
CY2022Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
46577
CY2023Q2 us-gaap Minimum Net Worth Required For Compliance
MinimumNetWorthRequiredForCompliance
35000000
CY2023Q2 bttx Minimum Bid Price Requirement Per Share For Listing
MinimumBidPriceRequirementPerShareForListing
1
CY2023Q2 bttx Minimum Market Value Of Listed Securities
MinimumMarketValueOfListedSecurities
35000000
CY2023Q2 bttx Minimum Consecutive Business Days Of Market Value Of Listed Securities
MinimumConsecutiveBusinessDaysOfMarketValueOfListedSecurities
P30D
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6600000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-134300000
us-gaap Net Income Loss
NetIncomeLoss
-22800000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-19700000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:4.4%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.4%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make certain estimates, judgments, and assumptions that affect the reported amounts of assets and liabilities and the related disclosures at the date of the financial statements, as well as the reported amounts of revenue and expenses during the periods presented. The estimates and assumptions used in the accompanying financial statements are based upon management’s evaluation of the relevant facts and circumstances. Such estimates, judgments, and assumptions include estimated costs for capitalized internal-use software, fair values of stock-based awards and valuation allowance for deferred tax assets. Actual results could be different from these estimates. To the extent there are material differences between these estimates, judgments, or assumptions and actual results, the Company's financial statements will be affected.</span></p>
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
36082
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
134045
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38495150
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38495150
CY2023Q3 bttx Accrued Service Providers Current
AccruedServiceProvidersCurrent
1753000
CY2022Q4 bttx Accrued Service Providers Current
AccruedServiceProvidersCurrent
1335000
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
238000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
506000
CY2022Q4 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
963000
CY2023Q3 us-gaap Interest Payable Current
InterestPayableCurrent
167000
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
168000
CY2022Q4 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
654000
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2158000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3626000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-5862000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-11405000
us-gaap Net Income Loss
NetIncomeLoss
-22808000
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
23693154
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
23693154
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
31214093
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
31214093
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
23533290
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
23533290
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.15
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.15
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.48
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.48
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.73
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.73
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.32
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.32
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5108585
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3932550
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3999223
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.95
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y3M18D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
64000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
984560
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.07
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1544
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.5
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
583154
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
4.19
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4399085
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.28
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y3M18D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.49
CY2023Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
2100000
bttx Unvested Restricted Stock Period
UnvestedRestrictedStockPeriod
P3M
CY2023Q3 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-1500000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1315000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1353000
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023Q3 us-gaap Litigation Reserve
LitigationReserve
1100000

Files In Submission

Name View Source Status
0000950170-23-061515-index-headers.html Edgar Link pending
0000950170-23-061515-index.html Edgar Link pending
0000950170-23-061515.txt Edgar Link pending
0000950170-23-061515-xbrl.zip Edgar Link pending
bttx-20230930.htm Edgar Link pending
bttx-20230930.xsd Edgar Link pending
bttx-ex31_1.htm Edgar Link pending
bttx-ex31_2.htm Edgar Link pending
bttx-ex32_1.htm Edgar Link pending
bttx-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
bttx-20230930_cal.xml Edgar Link unprocessable
bttx-20230930_pre.xml Edgar Link unprocessable
bttx-20230930_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
bttx-20230930_def.xml Edgar Link unprocessable
bttx-20230930_htm.xml Edgar Link completed
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending